Several brokerages have updated their recommendations and price targets on shares of Oscar Health (NYSE: OSCR) in the last few weeks:
- 5/9/2026 – Oscar Health was upgraded by Wall Street Zen from “hold” to “strong-buy”.
- 5/7/2026 – Oscar Health had its price target raised by UBS Group AG from $15.00 to $20.00. They now have a “neutral” rating on the stock.
- 5/7/2026 – Oscar Health had its price target raised by Barclays PLC from $18.00 to $21.00. They now have an “equal weight” rating on the stock.
- 5/7/2026 – Oscar Health was upgraded by Zacks Research from “hold” to “strong-buy”.
- 5/7/2026 – Oscar Health had its price target raised by Robert W. Baird from $15.00 to $19.00. They now have a “neutral” rating on the stock.
- 5/5/2026 – Oscar Health is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
- 4/21/2026 – Oscar Health had its “sell (d)” rating reaffirmed by Weiss Ratings.
- 4/20/2026 – Oscar Health was upgraded by Jefferies Financial Group Inc. from “underperform” to “hold”. They now have a $16.00 price target on the stock, up from $10.00.
Insider Buying and Selling at Oscar Health
In related news, CEO Mark T. Bertolini bought 1,000,000 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was purchased at an average cost of $11.92 per share, for a total transaction of $11,920,000.00. Following the purchase, the chief executive officer directly owned 10,196,876 shares in the company, valued at $121,546,761.92. This trade represents a 10.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Richard Scott Blackley sold 100,000 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $23.16, for a total transaction of $2,316,000.00. Following the transaction, the chief financial officer owned 1,216,660 shares of the company’s stock, valued at approximately $28,177,845.60. The trade was a 7.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 24.39% of the stock is owned by corporate insiders.
The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.
Featured Articles
- Five stocks we like better than Oscar Health
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Oscar Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oscar Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.
